These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 9056584)

  • 21. Bioequivalence of two film-coated tablets of imatinib mesylate 400 mg: a randomized, open-label, single-dose, fasting, two-period, two-sequence crossover comparison in healthy male South American volunteers.
    Parrillo-Campiglia S; Ercoli MC; Umpierrez O; Rodríguez P; Márquez S; Guarneri C; Estevez-Parrillo FT; Laurenz M; Estevez-Carrizo FE
    Clin Ther; 2009 Oct; 31(10):2224-32. PubMed ID: 19922893
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A method for the evaluation of individual bioequivalence.
    Endrenyi L
    Int J Clin Pharmacol Ther; 1994 Sep; 32(9):497-508. PubMed ID: 7820334
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tests for individual and population bioequivalence based on generalized p-values.
    McNally RJ; Iyer H; Mathew T
    Stat Med; 2003 Jan; 22(1):31-53. PubMed ID: 12486750
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Robust and bootstrap testing procedures for bioequivalence.
    Shen CF; Iglewicz B
    J Biopharm Stat; 1994 Mar; 4(1):65-90. PubMed ID: 8019585
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The multivariate assessment of bioequivalence.
    Chinchilli VM; Elswick RK
    J Biopharm Stat; 1997 Mar; 7(1):113-23. PubMed ID: 9056592
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alternative confidence intervals for the assessment of bioequivalence in four-period cross-over designs.
    Quiroz J; Ting N; Wei GC; Burdick RK
    Stat Med; 2002 Jul; 21(13):1825-47. PubMed ID: 12111892
    [TBL] [Abstract][Full Text] [Related]  

  • 27. On assessment of bioequivalence under a higher-order crossover design.
    Chow SC; Liu JP
    J Biopharm Stat; 1992; 2(2):239-56. PubMed ID: 1300216
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The assessment of individual and population bioequivalence.
    Chinchilli VM
    J Biopharm Stat; 1996 Mar; 6(1):1-14. PubMed ID: 8838775
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Individual bioequivalence: what matters to the patient.
    Hauck WW; Anderson S
    Stat Med; 1991 Jun; 10(6):959; discussion 959-60. PubMed ID: 1876785
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bioequivalence. An updated reappraisal addressed to applications of interchangeable multi-source pharmaceutical products.
    Marzo A; Balant LP
    Arzneimittelforschung; 1995 Feb; 45(2):109-15. PubMed ID: 7710428
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of the reference scaled bioequivalence semi-replicate method with other approaches: focus on human exposure to drugs.
    Karalis V; Symillides M; Macheras P
    Eur J Pharm Sci; 2009 Aug; 38(1):55-63. PubMed ID: 19524039
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Individual bioequivalence revisited.
    Chen ML; Lesko LJ
    Clin Pharmacokinet; 2001; 40(10):701-6. PubMed ID: 11707058
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sample size determination for bioequivalence assessment by means of confidence intervals.
    Diletti E; Hauschke D; Steinijans VW
    Int J Clin Pharmacol Ther Toxicol; 1992; 30 Suppl 1():S51-8. PubMed ID: 1601532
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized, open-label pharmacokinetic comparison of two oral formulations of fluconazole 150 mg in healthy adult volunteers.
    Jovanović D; Kilibarda V; Cirić B; Vucinić S; Srnić D; Vehabović M; Potogija N
    Clin Ther; 2005 Oct; 27(10):1588-95. PubMed ID: 16330294
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bayesian modeling of multivariate average bioequivalence.
    Ghosh P; Gönen M
    Stat Med; 2008 Jun; 27(13):2402-19. PubMed ID: 18095275
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multiple testing for bioequivalence with pharmacokinetic data in 2 x 2 crossover designs.
    Chen YI; Huang CS
    Stat Med; 2009 Dec; 28(28):3567-79. PubMed ID: 19760611
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Kullback-Leibler divergence for evaluating bioequivalence.
    Dragalin V; Fedorov V; Patterson S; Jones B
    Stat Med; 2003 Mar; 22(6):913-30. PubMed ID: 12627409
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sample size determination: extended tables for the multiplicative model and bioequivalence ranges of 0.9 to 1.11 and 0.7 to 1.43.
    Diletti E; Hauschke D; Steinijans VW
    Int J Clin Pharmacol Ther Toxicol; 1992; 30 Suppl 1():S59-62. PubMed ID: 1601533
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A distribution-free procedure for the statistical analysis of bioequivalence studies.
    Hauschke D; Steinijans VW; Diletti E
    Int J Clin Pharmacol Ther Toxicol; 1990 Feb; 28(2):72-8. PubMed ID: 2307548
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Asymmetry of the mean-variability tradeoff raises questions about the model in investigations of individual bioequivalence.
    Endrenyi L; Hao Y
    Int J Clin Pharmacol Ther; 1998 Aug; 36(8):450-7. PubMed ID: 9726700
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.